The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial[J]. Diabetes, 1995, 44(8): 968-983.
[2]
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)[J]. Lancet, 1998, 352(9131): 854-865.
[3]
ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2008, 358(24): 2560-2572.
[4]
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes[J]. N Engl J Med, 2009, 360(2): 129-139.
[5]
ACCORD Study Group, Gerstein HC, Miller ME, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes[J]. N Engl J Med, 2011, 364(9): 818-828.
[6]
Ziegler D. Type 2 diabetes as an inflammatory cardiovascular disorder[J]. Curr Mol Med, 2005, 5(3): 309-322.
[7]
Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia[J]. J Clin Endocrinol Metab, 2001, 86(5): 1930-1935.
[8]
Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study[J]. Diabetes Care, 2003, 26(7): 2015-2020.
[9]
Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population[J]. Lancet, 2002, 360(9326): 57-58.
[10]
Spranger J, Kroke A, M？hlig M, et al. Adiponectin and protection against type 2 diabetes mellitus[J]. Lancet, 2003, 361(9353): 226-228.
Knobler H, Benderly M, Boyko V, et al. Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose[J]. Eur J Endocrinol, 2006, 154(1): 87-92.
Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30[J]. J Clin Invest, 2001, 108(12): 1875-1881.
[16]
Kurzer E, Leveillee R, Bird V. Obesity as a risk factor for complications during laparoscopic surgery for renal cancer: Multivariate analysis[J]. J Endourol, 2006, 20(10): 794-799.
[17]
Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adiposespecic gene, adiponectin[J]. Int J Obes Relat Metab Disord, 2000, 24(7): 861-868.
[18]
Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome[J]. Proc Natl Acad Sci USA, 2000, 97(26): 14478-14483.
[19]
Stumvoll M, Tschritter O, Fritsche A, et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes[J]. Diabetes, 2002, 51(1): 37-41.
[20]
Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans[J]. Diabetes, 2002, 51(6): 1884-1888.
[21]
Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages[J]. Circulation, 2001, 103(8): 1057-1063.
[22]
Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity[J]. Nat Med, 2001, 7(8): 941-946.
[23]
Hernandez-Morante JJ, Milagro FI, Lujan JA, et al. Insulin effect on adipose tissue (AT) adiponectin expression is regulated by the insulin resistance status of the patients[J]. Clin Endocrinol (Oxf), 2008, 69(3): 412-417.
[24]
Festa A, D’Agostino R Jr, Tracy RP, et al. Elevated levels of acute phase proteins and plasminogen activeat or inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study[J]. Diabetes, 2002, 51(4): 1131-1137.
[25]
Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappa B and stimulates Ikappa B in mononuclear calls in obse subjects: evidence for an anti-inflammatory effect[J]. J Clin Endocrinol Metab, 2001, 86(7): 3257-3265.
